Table 2.
Clinical asthma markers of subjects with asthma by O3I status.
| Asthma, Low O3I (<8%) | Asthma, High O3I (≥8%) | p-Value * | Odds Ratio (95% CI) | |
|---|---|---|---|---|
| n | 185 | 57 | ||
| Age | 57.9 (42.8–66.4) | 54.6 (36.5–65.6) | 0.1938 ^ | |
| BMI (kg/m2) | 30.6 (26.9–37.7) | 31.7 (28.1–35.5) | 0.9591 ^ | |
| ICS (ug beclomethasone eq/d) | 1000 (500–2000) (n = 120) |
1000 (400–1000) (n = 51) |
0.019 | 0.999 (0.9989–0.9999) |
| ACQ6 | 0.7 (0.2–1.3) (n = 170) |
0.42 (0.2–1.11) (n = 24) |
0.311 | 0.71 (0.37–1.37) |
| GINA Classification: 1/2/3/4 (%) | 24/22/38/16 (n = 176) |
19/25/41/15 (n = 54) |
0.7638 # | |
| FEV1 (% predicted) | 79.11 ± 19.4 (n = 169) |
78.93 ± 16.78 (n = 54) |
0.610 | 1.00 (0.98–1.01) |
| FVC (% predicted) | 91.01 ± 16.82 (n = 169) |
91.71 ± 13.43 (n = 54) |
0.760 | 1.00 (0.98–1.02) |
| FEV1/FVC (%) | 70 (63–77) (n = 169) |
69.55 (59.78–75.33) (n = 54) |
0.249 | 0.98 (0.95–1.01) |
| CRP (mg/mL) | 3.8 (1.3–8.7) (n = 140) |
2.9 (1.1–7.8) (n = 44) |
0.124 | 0.94 (0.87–1.02) |
| IL-6 (pg/mL) | 1.8 (1.3–8.7) (n = 41) |
0.9 (0.1–1.7) (n = 41) |
0.212 | 0.85 (0.65–1.10) |
| TNF (pg/mL) | 1.3 (0.9–1.8) (n = 99) |
0.4 (0.2–1.2) (n = 37) |
0.944 | 1.01 (0.85–1.19) |
Data are presented as median (interquartile range) or mean ± standard deviation unless stated. Significant effects are highlighted in bold. ICS: inhaled corticosteroid; ACQ: Asthma Control Questionnaire; GINA: Global Initiative for Asthma; FEV1: Forced expiratory volume in 1 s; %; FVC: Forced vital capacity; CRP: C-reactive protein; IL-6: Interleukin-6; TNF-α: Tumour necrosis factor α. *: Logistic regression analysis performed, adjusting for age, gender and BMI unless otherwise stated. Reference population is low O3I. ^: Mann–Whitney test, unadjusted. #: Chi-squared test, unadjusted.